Northwire Canada EditionSunday, July 12, 2026
Northwire
GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0%
Other Material −

MyndTec Inc. Announces Inability to Secure Financing, Cessation of Operations and Evaluation of Strategic Alternatives Including Insolvency Proceedings

“Liquidity collapse forces MyndTec into insolvency review, casting doubt on any near‑term recovery.”

Executive Summary
  • On 8 Apr 2026 MyndTec announced it cannot secure additional financing and will run out of cash.
  • Principal shareholder Jim Anderson will not provide further capital; the company is in default on $1.12 M obligations and has negative working capital of $1.27 M.
  • An auditor’s going‑concern paragraph was added to FY 2024 statements.
  • The board engaged a Licensed Insolvency Trustee to explore restructuring, creditor proposals or asset sales; R&D has been halted and most staff laid off.
  • A trading halt was imposed earlier that day pending the material news.
Material Impact

The announcement is materially negative: it confirms that the company lacks any viable financing runway, triggers a going‑concern doubt, and initiates formal insolvency proceedings. This represents a step change from prior financing updates (private placements raising ~C$1.2 M total) and directly contradicts earlier expectations that the placement proceeds would sustain operations. The news is unexpected in magnitude; previous releases only hinted at cash constraints but never disclosed an imminent cessation of business.

MYTC · Price
Company Overview

MyndTec develops AI‑driven neuro‑rehabilitation software for stroke patients, marketed as a cloud‑based therapy platform. The technology has not yet generated commercial revenue; development costs have been funded primarily through private placements and the principal shareholder’s capital.

Read the original news release →

More from MyndTec Inc.